GlassScriptPhysician profile
Scott A Fulton
NPI 1861452237
$4,348.71
in general payments reported to CMS, 2019-2025
34 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $30.38 · 2021: $56.62 · 2022: $376 · 2023: $1,183 · 2024: $1,141 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,484 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.59 |
| Education | $111.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.05 | 2022-2025 | |
| Boston Scientific Corporation | $375.29 | 2019-2025 | Exalt Model D, Watchman Access System |
| Janssen Biotech, INC. | $293.72 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $277.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.25 | 2019-2025 | Xifaxan, Plenvu |
| Qol Medical, LLC | $226.24 | 2023-2025 | Sucraid, Sucraid |
| Neuraxis, INC. | $178.40 | 2025 | |
| Ardelyx, INC. | $167.27 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $163.09 | 2019-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $120.40 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Madrigal Pharmaceuticals | $101.03 | 2024-2025 | Resmetirom, Rezdiffra |
| Napo Pharmaceuticals INC | $95.81 | 2019 | |
| Aimmune Therapeutics, INC. | $91.96 | 2023-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $78.70 | 2022-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $77.28 | 2024-2025 | Iqirvo, Bylvay |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $76.96 | 2023-2024 | Hyrimoz |
| Daiichi Sankyo INC. | $72.68 | 2023-2024 | Injectafer |
| Lilly USA, LLC | $59.09 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $57.99 | 2024-2025 | Voquezna |
| Organon LLC | $55.91 | 2022-2024 | |
| Genzyme Corporation | $44.71 | 2022-2023 | |
| Braintree Laboratories, INC. | $43.98 | 2023-2024 | Sutab, Suflave |
| Amgen INC. | $36.67 | 2022-2023 | Amjevita, Avsola |
| Celltrion USA INC. | $32.32 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $31.01 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.77 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $26.49 | 2023 | Idacio |
| Celgene Corporation | $26.11 | 2021-2022 | |
| Vivus LLC | $20.94 | 2025 | Qsymia |
| Melinta Therapeutics, LLC | $19.61 | 2024 | Orbactiv, Kimyrsa, Rezzayo |
| Mauna Kea Technologies, INC. | $16.88 | 2024 | |
| Ferring Pharmaceuticals INC. | $15.62 | 2023 | Rebyota |
| La Jolla Pharmaceutical Company | $13.54 | 2023 | Xerava |
| Evoke Pharma, INC. | $13.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Fulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.